Spots Global Cancer Trial Database for sitravatinib
Every month we try and update this database with for sitravatinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies | NCT04518046 | Clear-Cell Rena... | Sitravatinib Nivolumab Ipilimumab | 18 Years - | Mirati Therapeutics Inc. | |
| Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer | NCT02219711 | Advanced Cancer | MGCD516 | 18 Years - | Mirati Therapeutics Inc. | |
| Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC | NCT05176925 | Non-small Cell ... | Tislelizumab Sitravatinib | 18 Years - 75 Years | Fudan University | |
| A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC | NCT05228496 | Lung Cancer, Sm... | Tislelizumab Sitravatinib | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer | NCT03015740 | Clear Cell Rena... Metastatic Kidn... Stage III Renal... Stage IV Renal ... | Laboratory Biom... Nivolumab Quality-of-Life... Questionnaire A... Sitravatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Sitravatinib in Metastatic Breast Cancer | NCT04123704 | Breast Cancer S... Triple Negative... Breast Neoplasm... Breast Cancer M... | Sitravatinib | 18 Years - | Baylor Breast Care Center | |
| Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC | NCT05176925 | Non-small Cell ... | Tislelizumab Sitravatinib | 18 Years - 75 Years | Fudan University | |
| Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma | NCT05104801 | Melanoma | sitravatinib tislelizumab | 18 Years - | Peking University Cancer Hospital & Institute | |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | NCT02664935 | Non-Small Cell ... Carcinoma, Squa... Adenocarcinoma | AZD4547 Vistusertib Palbociclib Crizotinib Selumetinib Docetaxel AZD5363 Osimertinib Durvalumab Sitravatinib AZD6738 | 18 Years - | University of Birmingham | |
| A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC | NCT05228496 | Lung Cancer, Sm... | Tislelizumab Sitravatinib | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | NCT02664935 | Non-Small Cell ... Carcinoma, Squa... Adenocarcinoma | AZD4547 Vistusertib Palbociclib Crizotinib Selumetinib Docetaxel AZD5363 Osimertinib Durvalumab Sitravatinib AZD6738 | 18 Years - | University of Birmingham | |
| Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy | NCT05614453 | Metastatic Cerv... | Tislelizumab Sitravatinib | 18 Years - | Australia New Zealand Gynaecological Oncology Group | |
| Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer | NCT04727996 | Advanced Biliar... | Sitravatinib Tislelizumab | 19 Years - | Seoul National University Hospital | |
| Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma | NCT03680521 | Clear Cell Rena... | Sitravatinib Nivolumab | 18 Years - | Mirati Therapeutics Inc. | |
| Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies | NCT04164199 | Advanced Malign... | Tislelizumab Pamiparib Temozolomide Sitravatinib Ociperlimab BAT1706 Fruquintinib BGB-15025 Zanidatamab BGB-A445 Surzebiclimab Lenvatinib LBL-007 | 18 Years - | BeiGene | |
| Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies | NCT04518046 | Clear-Cell Rena... | Sitravatinib Nivolumab Ipilimumab | 18 Years - | Mirati Therapeutics Inc. | |
| Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma | NCT05104801 | Melanoma | sitravatinib tislelizumab | 18 Years - | Peking University Cancer Hospital & Institute | |
| Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study | NCT04887870 | Advanced or Met... | Sitravatinib Nivolumab Pembrolizumab Enfortumab Vedo... Ipilimumab | 18 Years - | Mirati Therapeutics Inc. | |
| A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors. | NCT03666143 | Advanced Solid ... | Sitravatinib Tislelizumab | 18 Years - | BeiGene | |
| Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer | NCT03906071 | Metastatic Non-... | Nivolumab Sitravatinib Docetaxel | 18 Years - | Mirati Therapeutics Inc. | |
| Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma | NCT05461794 | Esophageal Squa... | Sitravatinib Tislelizumab Docetaxel Irinotecan | 18 Years - | BeiGene | |
| Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies | NCT04164199 | Advanced Malign... | Tislelizumab Pamiparib Temozolomide Sitravatinib Ociperlimab BAT1706 Fruquintinib BGB-15025 Zanidatamab BGB-A445 Surzebiclimab Lenvatinib LBL-007 | 18 Years - | BeiGene | |
| Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma | NCT05564338 | Hepatocellular ... | Sitravatinib Tislelizumab sitravatinib-ma... tislelizumab-ma... | 18 Years - | BeiGene | |
| A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) | NCT04734262 | Metastatic Brea... | Sitravatinib Tislelizumab Nab-paclitaxel | 18 Years - | Fudan University | |
| Sitravatinib in Metastatic Breast Cancer | NCT04123704 | Breast Cancer S... Triple Negative... Breast Neoplasm... Breast Cancer M... | Sitravatinib | 18 Years - | Baylor Breast Care Center | |
| A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors. | NCT03666143 | Advanced Solid ... | Sitravatinib Tislelizumab | 18 Years - | BeiGene | |
| A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) | NCT04734262 | Metastatic Brea... | Sitravatinib Tislelizumab Nab-paclitaxel | 18 Years - | Fudan University | |
| PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates | NCT04887194 | Advanced Solid ... | Sitravatinib Warfarin Dextromethorpha... Midazolam Digoxin Rosuvastatin Nivolumab | 18 Years - | Mirati Therapeutics Inc. | |
| Sitravatinib in Metastatic Breast Cancer | NCT04123704 | Breast Cancer S... Triple Negative... Breast Neoplasm... Breast Cancer M... | Sitravatinib | 18 Years - | Baylor Breast Care Center | |
| Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer | NCT04727996 | Advanced Biliar... | Sitravatinib Tislelizumab | 19 Years - | Seoul National University Hospital | |
| Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System | NCT05419817 | Recurrent Endom... Solid Tumors | pembrolizumab Sitravatinib | 18 Years - | University of Pittsburgh | |
| Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas | NCT02978859 | Liposarcoma Metastatic Lipo... | MGCD516 | 18 Years - | Columbia University | |
| Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer | NCT02954991 | Carcinoma, Non-... | Glesatinib Sitravatinib Mocetinostat Nivolumab | 18 Years - | Mirati Therapeutics Inc. | |
| Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults | NCT04472650 | Tumor | Sitravatinib Sitravatinib | 18 Years - 55 Years | BeiGene | |
| Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study | NCT03575598 | Squamous Cell C... Squamous Cell C... Squamous Cell C... | Sitravatinib Nivolumab | 18 Years - | University Health Network, Toronto | |
| Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma | NCT05564338 | Hepatocellular ... | Sitravatinib Tislelizumab sitravatinib-ma... tislelizumab-ma... | 18 Years - | BeiGene | |
| Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC | NCT04925986 | Carcinoma, Non-... Lung Diseases Lung Neoplasms Metastatic Lung... Stage IV Lung N... PD-L1 Gene Muta... Advanced Treatm... Sitravatinib Pembrolizumab | Sitravatinib Pembrolizumab | 18 Years - | Yale University | |
| Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study | NCT04887870 | Advanced or Met... | Sitravatinib Nivolumab Pembrolizumab Enfortumab Vedo... Ipilimumab | 18 Years - | Mirati Therapeutics Inc. | |
| Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies | NCT04518046 | Clear-Cell Rena... | Sitravatinib Nivolumab Ipilimumab | 18 Years - | Mirati Therapeutics Inc. | |
| Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma | NCT05104801 | Melanoma | sitravatinib tislelizumab | 18 Years - | Peking University Cancer Hospital & Institute | |
| Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC | NCT04925986 | Carcinoma, Non-... Lung Diseases Lung Neoplasms Metastatic Lung... Stage IV Lung N... PD-L1 Gene Muta... Advanced Treatm... Sitravatinib Pembrolizumab | Sitravatinib Pembrolizumab | 18 Years - | Yale University | |
| Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer | NCT03906071 | Metastatic Non-... | Nivolumab Sitravatinib Docetaxel | 18 Years - | Mirati Therapeutics Inc. | |
| Sitravatinib in Metastatic Breast Cancer | NCT04123704 | Breast Cancer S... Triple Negative... Breast Neoplasm... Breast Cancer M... | Sitravatinib | 18 Years - | Baylor Breast Care Center | |
| Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer | NCT03015740 | Clear Cell Rena... Metastatic Kidn... Stage III Renal... Stage IV Renal ... | Laboratory Biom... Nivolumab Quality-of-Life... Questionnaire A... Sitravatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer | NCT04904302 | Advanced Clear ... Metastatic Clea... Stage IV Renal ... | Nivolumab Quality-of-Life... Questionnaire A... Sitravatinib | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
